DrugPatentWatch Database Preview
Patents Expiring in May 2030
» See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms Intl | APRISO | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 022301-001 | Oct 31, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS | |||
| Ardelyx Inc | IBSRELA | tenapanor hydrochloride | TABLET;ORAL | 211801-001 | Sep 12, 2019 | DISCN | Yes | No | Start Trial | Start Trial | METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR | ||||
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | ||||
| Evoke Pharma Inc | GIMOTI | metoclopramide hydrochloride | SPRAY, METERED;NASAL | 209388-001 | Jun 19, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS | |||
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | Start Trial | Start Trial | Y | ||||
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | Start Trial | Start Trial | Y | ||||
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | RX | Yes | No | Start Trial | Start Trial | Y | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
